X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Torrent Pharma with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs DIVIS LABORATORIES - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA DIVIS LABORATORIES TORRENT PHARMA/
DIVIS LABORATORIES
 
P/E (TTM) x 44.8 38.4 116.8% View Chart
P/BV x 6.3 6.2 101.7% View Chart
Dividend Yield % 0.8 0.7 112.3%  

Financials

 TORRENT PHARMA   DIVIS LABORATORIES
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-18
DIVIS LABORATORIES
Mar-18
TORRENT PHARMA/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs1,5501,142 135.8%   
Low Rs1,144533 214.5%   
Sales per share (Unadj.) Rs354.7146.6 242.0%  
Earnings per share (Unadj.) Rs40.133.0 121.3%  
Cash flow per share (Unadj.) Rs64.238.4 167.2%  
Dividends per share (Unadj.) Rs14.0010.00 140.0%  
Dividend yield (eoy) %1.01.2 87.1%  
Book value per share (Unadj.) Rs273.1222.8 122.6%  
Shares outstanding (eoy) m169.22265.47 63.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.85.7 66.5%   
Avg P/E ratio x33.625.3 132.6%  
P/CF ratio (eoy) x21.021.8 96.2%  
Price / Book Value ratio x4.93.8 131.2%  
Dividend payout %34.930.3 115.4%   
Avg Mkt Cap Rs m227,897222,318 102.5%   
No. of employees `00014.710.8 136.6%   
Total wages/salary Rs m11,3534,561 248.9%   
Avg. sales/employee Rs Th4,083.03,616.0 112.9%   
Avg. wages/employee Rs Th772.3423.8 182.2%   
Avg. net profit/employee Rs Th461.3814.9 56.6%   
INCOME DATA
Net Sales Rs m60,02138,915 154.2%  
Other income Rs m2,9881,134 263.4%   
Total revenues Rs m63,00940,049 157.3%   
Gross profit Rs m13,49312,617 106.9%  
Depreciation Rs m4,0861,425 286.8%   
Interest Rs m3,08513 23,194.0%   
Profit before tax Rs m9,31012,313 75.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,5293,543 71.4%   
Profit after tax Rs m6,7818,770 77.3%  
Gross profit margin %22.532.4 69.3%  
Effective tax rate %27.228.8 94.4%   
Net profit margin %11.322.5 50.1%  
BALANCE SHEET DATA
Current assets Rs m52,62345,351 116.0%   
Current liabilities Rs m52,0226,507 799.4%   
Net working cap to sales %1.099.8 1.0%  
Current ratio x1.07.0 14.5%  
Inventory Days Days120127 94.4%  
Debtors Days Days7695 80.1%  
Net fixed assets Rs m85,01621,160 401.8%   
Share capital Rs m846531 159.4%   
"Free" reserves Rs m45,37658,625 77.4%   
Net worth Rs m46,22259,156 78.1%   
Long term debt Rs m41,1150-   
Total assets Rs m142,43267,832 210.0%  
Interest coverage x4.0926.8 0.4%   
Debt to equity ratio x0.90-  
Sales to assets ratio x0.40.6 73.5%   
Return on assets %6.912.9 53.5%  
Return on equity %14.714.8 99.0%  
Return on capital %14.220.8 68.1%  
Exports to sales %00-   
Imports to sales %021.8 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA8,485 0.0%   
Fx inflow Rs m14,58032,359 45.1%   
Fx outflow Rs m3,6009,042 39.8%   
Net fx Rs m10,98023,317 47.1%   
CASH FLOW
From Operations Rs m8,9427,759 115.3%  
From Investments Rs m-47,070-4,783 984.1%  
From Financial Activity Rs m34,174-3,142 -1,087.8%  
Net Cashflow Rs m-3,655-166 2,201.8%  

Share Holding

Indian Promoters % 71.5 52.0 137.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.0 11.8 59.5%  
FIIs % 12.6 19.0 66.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 17.2 51.2%  
Shareholders   26,511 31,796 83.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   ABBOTT INDIA  ALKEM LABORATORIES  AJANTA PHARMA  PFIZER  ALEMBIC PHARMA  

Compare TORRENT PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

TORRENT PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 13.3% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 13.3% YoY). Sales on the other hand came in at Rs 19 bn (up 36.2% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (1QFY19); Net Profit Up 50.8% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 50.8% YoY). Sales on the other hand came in at Rs 10 bn (up 21.2% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Sep 21, 2018 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA - DR. DATSONS LABS COMPARISON

COMPARE TORRENT PHARMA WITH

MARKET STATS